Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

We previously reported a phase 1b dose-escalation study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in relapsed or progressive multiple myeloma where the maximum planned dose (MPD) was carfilzomib 20 mg/m(2) days 1 and 2 of cycle 1 and 27 mg/m(2) days 8, 9, 15, 16, and thereafter;...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wang, Michael, Martin, Tom, Bensinger, William, Alsina, Melissa, Siegel, David S., Kavalerchik, Edward, Huang, Mei, Orlowski, Robert Z., Niesvizky, Ruben
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2013
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3814729/
https://ncbi.nlm.nih.gov/pubmed/24014245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-07-511170
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares